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cells (PBMC) by either free HIV-1 or trans infection by HIV bound to erythrocytes. Neutralization of free HIV-1
by b12 was stronger than by 4E10, but b12 neutralized erythrocyte-bound HIV-1 less efﬁciently than cell-free
virus. 4E10 did not neutralize erythrocyte-bound HIV-1 and at a low concentration it caused enhancement of
infection. Antibody (4E10)-dependent C activation inhibited trans infection by erythrocyte-bound HIV-1, but
caused enhanced infection with cell-free HIV-1 in the presence of erythrocytes. No effects of C were observed
with b12. C-dependent enhancement in the presence of erythrocytes is proposed as due to binding of C3b-
4E10-cell-free-HIV or C3d-4E10-cell-free-HIV to C receptor type 1 (CR1) on erythrocytes, or C receptor type 2
(CR2) on B cells in the PBMC, followed by trans infection of susceptible cells.Antigen Research, Division of
alter Reed Army Institute of
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In the transmission of HIV-1 the virus ﬁrst binds to a membrane
receptor on a target cell, such as both CD4 and a chemokine receptor
(CCR5 or CXCR4) that can serve as co-receptors. After penetration of
the plasma membrane of the cell by the virus via receptor-mediated
fusion, followed by intracellular replication, the newly assembled
virion can bud from the host cell into the extracellular environment
where it becomes a cell-free infectious virus. Upon encountering a
new target cell a new cycle leads to entry and infection of the new cell
(Levy, 2007). Numerous in vitro assays have been devised to detect
antibodies that interfere with (i.e., neutralize) receptor-mediated
binding and fusion with target cells (Polonis et al., 2008). In most
assays, free virus collected from infected cultured cells is incubated
with new target cells in the presence of antibodies being tested for
neutralizing activity. Often a single well-deﬁned cell type or cell line is
used as a target for infection, and plasma (or serum) that is used as the
source of antibodies is pre-heated to inactivate complement (C).
Although this type of neutralization assay has the useful advantage ofreducing complexity for high throughput in vitro assays, it may not
accurately reﬂect events that occur in vivo that not only include
antibody-dependent innate effector mechanisms, but also include
complex biological interactions of the virus with other types of cells
that either lack the CD4 receptor or that have alternative types of
receptors or binding sites for HIV-1. Among such innate effector
mechanisms are included antibody-dependent complement (C)
activation, and a variety of effects involving binding of IgG to Fc
receptors (Monteﬁori, 1997; Beck et al., 2008; Stoiber et al., 2008).
Although it is known that innate effector mechanisms can be
effective for preventing HIV-1 infection, they are also sometimes
utilized by HIV-1 in order to enhance, rather than inhibit, cellular
entry of the virion and thereby promote infection (Monteﬁori, 1997;
Huber et al., 2006; Huber and Trkola, 2007; Willey and Aasa-
Chapman, 2008). For example, C-mediated enhancement of infection
has been described, and Fc-mediated endocytosis of HIV-1 can also
lead to productive infection (Takada and Kawaoka, 2003; Beck et al.,
2008; Stoiber et al., 2008).
It has recently been observed that human erythrocytes (which lack
both CD4 and chemokine receptors), and other CD4-negative cells,
exhibit spontaneous calcium-dependent cell surface binding (i.e.,
adsorption) of infectious HIV-1 particles in vitro (Beck et al 2009).
Although only a small fraction (amean of only 2.3%) of the total added
HIV-1 p24 was bound to erythrocytes, this small fraction comprised
Fig. 1. Neutralization of cell-free HIV-1 89BZ_167 by 4E10 and b12. The values in A and
B frames represent the means (±SEM) of 7 and 6 independent experiments,
respectively. The dashed lines indicate the level (50%) deﬁned as a positive cutoff for
inhibition of virus growth.
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non-infectious, incomplete, or degraded particles (Beck et al., 2009).
Although the molecular adhesion molecule responsible for binding of
HIV-1 to erythrocytes is still unknown, after adsorption of HIV-1 to
the erythrocyte cell surface the cell-bound HIV-1 was approximately
100-fold more potent (based on total p24 input) than cell-free HIV-1
for causing infection of permissive CD4-positive cells through a
process referred to as infection in trans (Beck et al., 2009). This
observation thus raised the possibility that “free” infectious HIV-1
might occur only rarely in vivo, and even suggested the possibility that
erythrocyte-bound virus might be an important infectious agent for
transmitting HIV-1 in blood.
In view of the above interactions of HIV-1 with erythrocytes, the
question arose whether antibodies that neutralize infection by cell-
free virus can also neutralize trans infection caused by erythrocyte-
bound HIV-1. To address this, we utilized two well-known and
important, but rare, human IgG monoclonal antibodies (mAbs), 4E10
and b12, that broadly neutralize cell-free virus (Klein et al., 2009). Our
goal was to determine whether mAbs that neutralize infection of
human peripheral blood mononuclear cells (PBMC) by free HIV-1
would similarly neutralize trans infection mediated by erythrocyte
surface-bound HIV-1. In addition, we examined the effects of
antibody-dependent C activation on either infection of PBMC by
cell-free virus or trans infection from erythrocytes to PBMC.
The use of PBMC from human donors as target cells for infection
has the advantage that PBMC comprise a complex mixture of primary
cells that include not only CD4-positive lymphocytes, but also
monocytes, NK cells, and numerous other mononuclear cells. The
presence of different types of cells in the PBMC population might
provide important effector mechanisms that could impact the process
of speciﬁc receptor-dependent infection of lymphocytes or other cells.
In the course of the work, we discovered that erythrocyte-bound HIV-
1 was much more resistant than free HIV-1 to neutralization by two
mAbs, 4E10 and b12, that broadly neutralize infection by free virus.
Under certain circumstances some degree of enhancement of
infection of PBMC could be observed with 4E10. In addition, we also
discovered that depending on the mechanism used for binding of the
infectious HIV-1 to erythrocytes, C-dependent inhibition or C-
dependent enhancement of trans infection to PBMC could also be
observed with 4E10.
Results
Antibody-mediated neutralization of HIV-1 in the absence of
complement
HumanmAbs 4E10 and b12 each neutralized cell-free HIV-1 in the
absence of C, resulting in dose-dependent reduction of proliferation of
HIV-1 in human PBMC and decreased production of p24. A 50% level of
neutralization, calculated as IC50, is often used as a standard
benchmark for determining signiﬁcant effectiveness of neutralization
(Brown et al., 2005). As shown in Fig. 1, 4E10 and b12 both achieved
50% neutralization, but b12 (Fig. 1B) was more potent than 4E10
(pb0.0001) (Fig. 1A). Because the PBMC assay employs a mixture of
cells obtained from normal donors, variability is often observed
among different individual assays, and the results of Fig. 1 are
illustrated as the means±S.D. (n=7).
The relative degree of variability of neutralization of free virus by
4E10 is shown for four individual experiments in Fig. 2A–D, and
neutralization of erythrocyte-bound HIV-1 was also examined in the
same experiments (Fig. 2E–H). In contrast to neutralization of free
virus by 4E10, 50% neutralization of cell-bound HIV-1 by 4E10 was
observed at only one point (the highest antibody level) in a single
experiment (Fig. 2F). However, in every experiment, 4E10 caused
N50% enhancement of infection (shown as N−50% neutralization)
(Fig. 2E–H), and N100% enhancement of infection was even observedin one experiment (Fig. 2F). It is clear that 4E10 had less ability to
neutralize erythrocyte-bound HIV-1 than cell-free virus, and some
degree of enhancement of infectionmight even have occurred. Fig. 3A,
which shows the means±S.D. of six experiments, indicates that
enhancement by 4E10 was signiﬁcant at a single dose (0.25 μg) of
4E10 (pb0.05). Although b12 is the more potent neutralizing
antibody with free virus, the IC50 of b12 required for neutralization
of cell-bound HIV-1 (IC50=25.2 μg/ml) (Fig. 3B) was 12-fold higher
than the IC50 required for neutralization of cell-free HIV-1
(IC50=2.1 μg/ml). The differences between the curves shown in
Figs. 1A vs. 3A and Figs. 1B and 3B, respectively, were signiﬁcant
(pb0.0001). From this series of experiments with two mAbs having
different HIV-1 envelope binding speciﬁcities, we conclude that
antibody-mediated neutralization of erythrocyte-bound HIV-1 is
more difﬁcult to achieve than neutralization of cell-free HIV-1.
Antibody-dependent complement-mediated effects
Although most antibody-mediated in vitro neutralization assays are
performed in the absence of C, it is obvious that C could be an important
effector mechanism for antibody-dependent neutralization of HIV-1 in
vivo. Thus, we examined neutralization of HIV-1 by 4E10 in the
presence and absence of complement. In planning these experiments,
we hypothesized that two possible mechanisms might inﬂuence the
effects of added C. In the Type 1 mechanism, if the HIV-1 were initially
bound to erythrocytes through a C-independent mechanism, perhaps
through binding to an integrin or other surface binding site (Beck et al.,
2009), then the HIV-1 could be vulnerable to antibody-dependent
activation of the C cascade through C9 and the membrane attack
complex, and lysis of the erythrocyte-bound HIV-1 might occur. In the
Type 2 mechanism, if aqueous immune complexes of mAb, C, and cell-
free HIV-1 were associated with the erythrocytes through binding of
the HIV-mAb-C3b to erythrocytic complement receptor type 1 (CR1)
(CD35), the HIV-1 would remain on the erythrocytes as infectious viral
particles (Zhou and Monteﬁori, 1996). This might therefore facilitate,
Fig. 2. Neutralization by 4E10 of HIV-1 89BZ_167 infection of PBMC. (A–D) Cell-free HIV was used as the virus source for direct infection of PBMC; (E–H) erythrocyte-bound HIV-1 was
used as the virus source for trans infection of PBMC. Each of the eight graphs represents a single experiment; 4 sets of paired experiments (A, E; B, F; C, G; D, H) with free vs. erythrocyte-
bound HIV-1 were each performed on the same day, but similar results were obtained in a total of 7 experiments with free HIV-1, and 6 experiments with erythrocyte-bound HIV-1. The
dashed lines indicate the level (50%) deﬁned as a positive cutoff for inhibition of virus growth, or the levels (−50% and−100%) deﬁned as enhancement of infection.
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erythrocyte immune complex by PBMC (see Discussion for detailed
descriptions of potential mechanisms).
To achieve the Type 1 mechanism, we pre-incubated cell-free HIV-1
with erythrocytes to allow binding to the cells in the absence of C, then
washed the cells to remove unbound HIV-1, and added 4E10 and C,
followed by further washing of the cells. To achieve the Type 2
mechanism, we added cell-free HIV-1 to a mixture of themAb (4E10 or
b12) and C, and then added erythrocytes to the mixture. The predicted
results of the Type 1 and Type 2 experiments were each consistently
observed, as shown in Fig. 4. In each of six experiments, pre-incubation
of HIV-1 with erythrocytes (cell-bound HIV-1), followed by subsequent
addition of 4E10+C inhibited infection of PBMCwhen compared to the
absence of C (the Type 1 mechanism) (p=0.0008 for comparison of
column 1 in experiments A–E with column 2 in experiments A–E)
(Fig. 4). In contrast, addition of cell-free HIV-1 to the mixture of 4E10
+C, followed by incubation with erythrocytes, resulted in enhanced
infection of PBMC when compared to the absence of C (the Type 2
mechanism) (pb0.0001 for column 3 in experiments A–E compared to
column 4 in experiments A–E). Fig. 5 (upper frames) shows that N50%
neutralization of erythrocyte-bound HIV-1 (mean of relative neutral-ization observed in 8 separate experiments) was caused by C (column
1), and 50% enhancement (−50% neutralization) of infection by cell-
free HIV-1 was caused by C (column 4). Both the enhancement and the
inhibition of infection were eliminated when C was inactivated either
by heat (Fig. 5 upper frames, columns 2 and 5) or by treatment with
zymosan (columns 3 and 6).
In contrast to the results obtained with the 4E10 mAb, neither C-
mediated neutralization nor C-mediated enhancement with cell-
bound or cell-free HIV-1was observed in 6 separate experiments with
b12 (Fig. 5, lower frames). We conclude from this in vitro result that C
does not serve as an effector mechanism either for neutralization or
enhancement by b12, a ﬁnding that is consistent with results of in vivo
passive protection studies with b12 in macaques (Hessell et al., 2007).
Discussion
Effects of antibodies on infectivity of PBMC by free vs. erythrocyte-bound
HIV-1
In this study we found that two human IgG mAbs, b12 and 4E10,
both of which are recognized as important models of antibodies that
Fig. 3. Neutralization by 4E10 and b12 of trans infection by erythrocyte-bound HIV-1
89BZ_167. The values in frames A and B represent the means (±SEM) of 6 and 5
independent experiments, respectively. A. Enhancement (N−50% neutralization) by
0.25 μg/ml of 4E10 of trans infection by erythrocyte-bound HIV-1 was signiﬁcantly
different from the data shown for the 0, 16 and 64 μg/ml doses (pb0.05).
Fig. 4. Effects of antibody (4E10)-dependent C activation on infection of PBMC by cell-
free HIV-1Bal vs. trans infection of PBMC by erythrocyte-bound HIV-1Bal-mAb
complexes. The data are the means of 4 determinations, and each of the six frames
(A–F) represents two independent paired experiments using either cell-bound HIV-1 or
cell-free HIV-1. In each case, 4E10 had been pre-incubated with the cell-bound or cell-
free HIV-1, followed by addition of C, as indicated.
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of trans infection of PBMC by erythrocyte-bound HIV-1. The 4E10mAb
not only did not neutralize trans infection by cell-bound HIV-1, but
at a low concentration it caused enhancement of infection. These
observations could have implications regarding the vulnerability of
HIV-1 in vivo to neutralization by circulating antibodies. In light of the
previous discovery that erythrocytes can bind all of the infectious HIV-
1 virions in vitro through a C-independent mechanism (Beck et al.,
2009), the present results suggest that erythrocytes, or other CD4-
negative cells, might serve as important immunologically protected
reservoirs for HIV-1 infection. These observations also raise the
possibility that in vitro neutralizing antibody assays that employ cell-
free virus as the infecting agent with cell lines as targets as might
not detect antibodies that can cause enhanced infection at certain
concentrations that is observed with PBMC as targets for infection.
In the interactions of the mAbs with cell-free virus, Fc-mediated
activation of NK cells in the PBMC might be expected to cause
inhibition of infection (Hessell et al., 2007; Perez et al., 2009; Forthal
and Moog, 2009). However, Fc-mediated uptake via endocytosis of
monocytes in the PBMC might also promote enhanced infection of
the cells (Takeda et al, 1988; Homsy et al., 1990; Takada and
Kawaoka, 2003; Huisman et al., 2009). Competition between these
two opposing mechanisms in the PBMC population might be
inﬂuenced by the relative concentrations of NK cells vs. monocytes,
and this competition could also be inﬂuenced by the relative
tendencies of the two mAbs to promote interactions with each
type of cell. Although the data do not allow a deﬁnitive explanation
of the enhancement of infection of free virus observed by us with
4E10 in the absence of C, neutralization by 4E10 (but not b12) is
potentiated by interactions with either Fcγ receptor I (FcγRI) or IIb
(FcγRIIb) but not by FcγRIII (Perez et al., 2009). However, it has also
been reported that interaction of antibodies with FcγRIII might be
responsible for Fc-mediated enhancement of HIV infection of human
cells (Homsy et al., 1989). Thus, it is possible that antibody-mediatedenhancement observed with 4E10in the absence of C is due to
interactions of the antibody with FcγRIII that is present on
permissive cells in the PBMC.
Fig. 5. Effects of antibody-dependent C activation on the trans infection of PBMC by
erythrocyte-bound HIV-1-mAb complexes. A. Data with 4E10 are the mean±SEM of
8 experiments similar to those shown in Fig. 4. B. Data with b12 are the mean±SEM of
6 experiments. The baselines represent the values obtained in the absence of C, HI-C, or
Zy-C. The dashed lines indicate the levels of 50% or−50%, deﬁned as positive cutoffs for
inhibition or enhancement of virus growth, respectively. In each case, 4E10 had been
pre-incubated with the cell-bound or cell-free HIV-1, followed by addition of C, HI-C, or
Zy-C, as indicated. Abbreviations: C,s complement; HI-C, heat-inactivated C; Zy-C, C
inactivated by treatment with zymosan.
Fig. 6. Schematic representation of C-dependent neutralization of erythrocyte-bound
virus (A), and C-dependent enhancement of infection of PBMC by cell-free virus (B). A.
After antibody-independent and C-independent binding of HIV-1 to erythrocytes (Beck
et al., 2009), binding of 4E10 (Fig. 4A), but not b12 (Fig. 4B), to the erythrocyte-bound
HIV-1 results in C-dependent neutralization (“type 1” mechanism, resulting in lysis of
HIV-1; see text for details). B. Binding of 4E10 (Fig. 4A), but not b12 (Fig. 4B), to cell-free
HIV-1 results in C-dependent binding to CR1 on erythrocytes or B cells, or CR2 on B cells,
with enhanced infection of PBMC through trans infection of PBMC by erythrocyte-
bound or B cell-bound HIV-1 (“type 2” mechanism, resulting in enhancement of HIV-1
infection; see text for details).
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HIV-1 itself that would inﬂuence the binding to CD4 and fusion with
the CD4+ target cell. Although the 4E10 mAb does exhibit direct
binding to HIV-1, it is relatively weak (Peachman et al., 2010; Leaman
et al., 2010), and it is generally believed that 4E10 exerts its inhibitory
effects at least partly by interfering with the fusion process with the
target cell (Frey et al., 2008, 2010). In the present work, after
incubation of erythrocyte-bound HIV-1 with the mAb the erythro-
cytes were washed free of unbound mAb and, because of weak
binding of HIV-1 by 4E10 (Peachman et al., 2010), this thereforemight
have reduced the ability of 4E10, but not b12, to interfere with the
binding and fusion of the erythrocyte-bound HIV-1 with susceptible
CD4+ T cells during the process of trans infection.
Effects of antibody-dependent C activation on infectivity of free vs.
erythrocyte-bound HIV-1
The role of C as an antibody-dependent effector mechanism for
inﬂuencing the infectivity of HIV-1 has been controversial. Some
studies have demonstrated C-dependent lysis of HIV-1 (Aasa-
Chapman et al., 2005; Huber et al., 2006), and others have
demonstrated C-dependent enhancement of infection (Prohaszka et
al., 1997; Stoiber et al., 2005; Robinson, 2006; Beck et al., 2008). A
study that used b12 as a model mAb further suggested that b12-
dependent C activation exerted no important protective or enhancing
effects on infectivity following challenge with SHIV in a macaque
model (Hessell et al., 2007). In the present work we found that b12
exhibited neither C-mediated neutralization nor enhancement of
trans infection by erythrocyte-bound HIV-1 (Fig. 5, lower frames).
However, in contrast to b12, the 4E10 mAb exhibited both C-
dependent lysis and C-dependent enhancement of trans infection of
erythrocyte-bound HIV-1, and the effects depended on whether C
activation was caused by a cell-bound immune complex consisting of
4E10-HIV-1-erythrocyte, or whether C activation was induced by
4E10 binding to cell-free HIV-1 (Fig. 5, upper frames).To explain the different effects of C observed with 4E10, we
propose two different ways inwhich C could be expected to play a role
in the presence of HIV-1-mAb immune complexes (Fig. 6). In the type
1 mechanism (Fig. 6A), we found that if the erythrocyte-bound HIV-1
was ﬁrst exposed to 4E10, then washed free of unbound 4E10, and
exposed to C, neutralization of trans infection was observed. In
contrast, in the type 2 mechanism (Fig. 6B), if we ﬁrst exposed cell-
free HIV-1 to both 4E10 and C, followed by incubation with
erythrocytes, then enhancement of infection of PBMC was observed.
The type 2 mechanism of C-mediated enhancement of free HIV-1-
4E10 complexes presumably proceeded by binding of the immune
complex to C receptor type 1 (CR1), leading to binding of C3b, and
then followed by uptake by phagocytic cells via the C3b receptor
(Fig. 6B). This mechanism is the normal manner for removal of
circulating immune complexes (Schifferli et al., 1986; Khera and Das,
2009). It is believed that the HIV-1 remains viable after attachment to
CR1 (Khera and Das, 2009), and uptake by phagocytic cells, or trans
infection of CD4+ cells, could explain the enhancement observed in
Figs. 4 and 5. In contrast, the type 1 mechanism does not involve
binding of HIV-1 to CR1 because the HIV-1 is already bound to
another, as yet unknown, site on the erythrocyte (Beck et al., 2009)
(Fig. 6A). At this location, assuming that erythrocyte-bound HIV does
not have direct access via cis binding to CR1 on the erythrocyte, the
HIV particle would then be vulnerable to direct binding of 4E10
(Peachman et al., 2010; Leaman et al., 2010), resulting in activation of
the classical C pathway. This latter process would interfere with the
infectivity by generation of the membrane attack complex of C that
would punch holes in the lipid bilayer of the virion.
The degree to which C-mediated enhancement vs. lysis of HIV-1
would occur would thus depend on the relative degree of C-
independent binding of HIV-1 to erythrocytes vs. the degree of
antibody binding to free virus followed by C activation and uptake by
erythrocytic CR1, as summarized in Fig. 6. It should be pointed out that
after binding of the HIV-1-4E10-C3b complex to CR1 the C3b would
also be expected to degrade to iC3b and C3d, which could result in the
transfer of the HIV particles to complement receptor type 2-
expressing B-cells, which could then be subjected to B-cell mediated
transfer to T-cells (Banki et al 2006; Khera and Das 2009) (Fig. 6B).
Although the interactions of HIV-1 with C might therefore be quite
446 Z. Beck et al. / Virology 412 (2011) 441–447complex, the basic principle remains that initial antibody-indepen-
dent and C-independent binding of HIV-1 to erythrocytes (Beck et al.,
2009) could reasonably explain the inhibitory effect of antibody and C
observed in our type 1 mechanism (Fig. 4A–C, ﬁrst bars; and Fig. 5 top
panel, ﬁrst bar).
We conclude from this in vitro study that antibody-mediated
neutralization of erythrocyte-bound HIV-1 may be much less efﬁcient
than neutralization of cell-free HIV-1. In addition, with certain
antibodies, such as b12, neither antibody-dependent complement-
mediated neutralization nor enhancement of infectivity of PBMC by
erythrocyte-bound HIV-1 may occur. However, with other antibodies,
such as 4E10, antibody-dependent activation of C may cause either
neutralization or enhancement of trans infection of PBMC by
erythrocyte-bound HIV-1 depending on whether the HIV-1 is cell-
free or cell-bound at the time of C activation. Although the hypotheses
we have presented are consistent with the data observed, it should be
pointed out that the mechanistic effects of antibodies attached to
erythrocyte-bound HIV might be even more complex than we have
suggested. For example, the possibility exists that C activation by
immune complexes of mAb-HIV on erythrocytes might also lead to
hemolysis of the erythrocyte itself, in addition to lysis of the infectious
HIV particle bound to the erythrocyte. At present, hemolysis, if it
occurs, would be too small to observe easily in the type of
experimental system described in this study.
Materials and methods
Cells, viruses, antibodies, and complement
Peripheral blood mononuclear cells (PBMC) were collected by
leukapheresis under an IRB-approved protocol. Erythrocytes used for
binding were separated from PBMC by Ficoll-hypaque puriﬁcation,
washed 3 times in PBS, and stored in ADSOL storage medium at 4 °C.
Primary isolates of HIV-1 clade B, 89BZ_167 and Bal were propagated
as previously described (Brown et al., 2005). Human monoclonal IgG
antibodies 4E10 and b12 were purchased from Polymun Scientiﬁc
GmbH (Vienna).
Pooled normal human serum (United States Biological, Swamps-
cott, MA) was used as a source of C. Inactivated C, where indicated,
was obtained either by heating at 56 °C for 45 min, or by treatment
with zymosan A (purchased from Sigma-Aldrich, St. Louis, MO).
Zymosan A (110 μl of 5 mg/ml of in PBS) was added to 1 ml of serum,
incubated at 37 °C for 90 min, followed by centrifugation to remove
the zymosan particles.
Neutralization assays
Neutralization with free virus was performed as described (Brown
et al., 2005). In brief, virus stock (100 μl of a 1/20 dilution in IL-2
medium) was incubated with 20 μl of mAb at the indicated
concentrations in PBS for 30 min at 37 °C. The mixture was then
added to 50 μl of 1.5×105 PHA-stimulated PBMC/well. Binding of HIV-
1 to erythrocytes and trans infection of PBMC by erythrocyte-bound
HIV-1 was previously described (Beck et al., 2009). Although only a
small fraction of the total p24 present in the free virus preparation
(approximately 2.3%) became bound to the erythrocytes, the
erythrocyte-bound p24 comprised essentially all of the infectious
particles originally present in the free virus (Beck et al., 2009). Thus,
although the total inputs of p24 of the free and erythrocyte-bound
viruses were different, the total numbers of infectious particles were
essentially the same. Erythrocytes (5×108 in 100 μl of RPMI) were
incubated with 20 μl of indicated dilutions of mAb in PBS for 30 min at
37 °C. Unbound antibody was removed by centrifugation; cells were
resuspended in 100 μl of IL-2 medium; and added to 50 μl of PHA-
stimulated PBMC. After incubation in 96-deep-well plates at 37 °C
overnight, the cells were transferred to 96-well-round-bottom plates,and 70 μl of IL-2 medium were added to each well. On days 4 and 6
post-infection, 50 μl of culture ﬂuid was harvested and assayed for
p24 using a p24 antigen capture kit (ABL). In order to have a sufﬁcient
range of measurement for virus neutralization or enhancement, the
data were calculated using the day of harvest upon which the control
(virus with cells alone) level of infection was N10,000 pg/ml. This
varied slightly depending both on the virus inoculum and on the HIV
seronegative donor PBMC that were used as target cells. Neutraliza-
tion or enhancement was deﬁned as 50% decrease, or 50% increase, of
virus production, respectively.
Complement-dependent neutralization of erythrocyte-bound HIV-1
HIV-1BAL was ﬁrst bound to erythrocytes at 4 °C (Beck et al., 2009).
mAbwas then added to a ﬁnal concentration of 1 μg/ml and incubated
at 37 °C for 30 min. After washing by centrifugation, erythrocytes
containing bound HIV-1 andmAb (1.5×109 cells) in 300 μl RPMI were
incubated with 100 μl of C, heat-inactivated C, zymosan-treated C, or
RPMI for 30 min at 37 °C. The erythrocytes were washed by
centrifugation, resuspended in 600 μl of IL-2 medium, 100 μl was
added to 50 μl of stimulated PBMC (1.5×105), and then added in
quadruplicate to 96-well cell culture plates. After overnight incuba-
tion, 70 μl/well of IL-2 medium was added, and p24 was measured on
day 4 and 6 post-infection.
Complement dependent enhancement of cell-free HIV-1
Undiluted HIV-1Bal stock (300 μl) was incubated with mAb in a
ﬁnal concentration of 1 μg/ml for 30 min at 4 °C. The HIV-1-mAb
mixture was incubated with 100 μl of C, heat-inactivated C, zymosan-
treated C, or RPMI for 30 min at 4 °C. Erythrocytes (1.5×109) in 300 μl
of RPMI were added and incubated for 1.5 h at 37 °C. After washing 3
times by centrifugation, the pellet was resuspended in 600 μl of IL-2
medium. Trans infection of PBMC was then assayed as in the assay for
neutralization of erythrocyte-bound HIV-1 (see above).
Statistical analysis
The data were analyzed using the D'Agostino–Pearson normality
test. The number of samples (6–7) was too small to determine the
distribution of the data. The data were assumed to be normally
distributed and the following statistical analyses were performed.
Neutralization of infection by free virus and of trans infection by
erythrocyte-bound virus were compared using a two-way ANOVA test
with Bonferroni post tests. For comparison of C-dependent neutral-
ization and C-dependent enhancement, the paired T-test with one tail
was used. The apparent enhancement (N−50% neutralization) by
0.25 μg/ml of 4E10 of trans infection by erythrocyte-bound HIV-1,
shown in Fig. 3, was compared with the data shown for the 0, 16 and
64 μg/ml doses using one-way ANOVA with Newman–Keuls multiple
comparison test.
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